DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Uloric (Febuxostat) - Indications and Dosage

 



INDICATIONS AND USAGE

ULORIC® is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout.

ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.

DOSAGE AND ADMINISTRATION

Recommended Dose

For treatment of hyperuricemia in patients with gout, ULORIC is recommended at 40 mg or 80 mg once daily.

The recommended starting dose of ULORIC is 40 mg once daily. For patients who do not achieve a serum uric acid (sUA) less than 6 mg per dL after 2 weeks with 40 mg, ULORIC 80 mg is recommended.

ULORIC can be taken without regard to food or antacid use [see Clinical Pharmacology].

Special Populations

No dose adjustment is necessary when administering ULORIC in patients with mild to moderate renal impairment [see Use in Specific Populations and Clinical Pharmacology]. The recommended starting dose of ULORIC is 40 mg once daily. For patients who do not achieve a sUA less than 6 mg per dL after 2 weeks with 40 mg, ULORIC 80 mg is recommended.

No dose adjustment is necessary in patients with mild to moderate hepatic impairment [see Use in Specific Populations and Clinical Pharmacology].

Uric Acid Level

Testing for the target serum uric acid level of less than 6 mg per dL may be performed as early as 2 weeks after initiating ULORIC therapy.

Gout Flares

Gout flares may occur after initiation of ULORIC due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits. Flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended upon initiation of ULORIC. Prophylactic therapy may be beneficial for up to six months [see Clinical Studies].

If a gout flare occurs during ULORIC treatment, ULORIC need not be discontinued. The gout flare should be managed concurrently, as appropriate for the individual patient [see Warnings and Precautions].

DOSAGE FORMS AND STRENGTHS

  • 40 mg tablets, light green to green, round shaped, debossed with "TAP" and "40"
  • 80 mg tablets, light green to green, teardrop shaped, debossed with "TAP" and "80"

HOW SUPPLIED/STORAGE AND HANDLING

ULORIC 40 mg tablets are light green to green in color, round shaped, debossed with "TAP" on one side and "40" on the other side and supplied as:

NDC Number Size
64764-918-11Hospital Unit Dose Pack of 100 Tablets
64764-918-30Bottle of 30 Tablets
64764-918-90Bottle of 90 Tablets
64764-918-18Bottle of 500 Tablets

ULORIC 80 mg tablets are light green to green in color, teardrop shaped, debossed with "TAP" on one side and "80" on the other side and supplied as:

NDC Number Size
64764-677-11Hospital Unit Dose Pack of 100 Tablets
64764-677-30Bottle of 30 Tablets
64764-677-13Bottle of 100 Tablets
64764-677-19Bottle of 1000 Tablets

Protect from light. Store at 25°C (77°F); excursions permitted to 15°– 30°C (59°– 86°F) [See USP Controlled Room Temperature]

Page last updated: 2009-02-23

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009